Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Phase I study of mesenchymal stem cell (MSC)-derived exosomes with KRASG12D siRNA in patients with metastatic pancreatic cancer harboring a KRASG12D mutation.
Authors
Rishi Surana
Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Rishi Surana , Valerie S. LeBleu , J. Jack Lee , Brandon George Smaglo , Dan Zhao , Michael Sangmin Lee , Robert A. Wolff , Michael J. Overman , Mayela C. Mendt , Kathleen M. McAndrews , Sujuan Yang , Katy Rezvani , Raghu Kalluri , Anirban Maitra , Elizabeth J. Shpall , Shubham Pant
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03608631
DOI
10.1200/JCO.2022.40.4_suppl.TPS633
Abstract #
TPS633
Poster Bd #
Q9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase I study of hydroxychloroquine plus binimetinib in patients with metastatic pancreatic cancer (the HOPE trial).
First Author: Rishi Surana
Poster
2022 ASCO Annual Meeting
Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer.
First Author: Manish Sharma
Poster
2021 ASCO Annual Meeting
Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).
First Author: Lucy Xiaolu Ma
Poster
2012 ASCO Annual Meeting
A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.
First Author: Jean-Luc Van Laethem